Background: The Bone Morphogenetic Protein (BMP) family acts as a critical modulator of cellular plasticity and lineage commitment in oncogenesis. However, the systematic contribution of BMP-related mRNAs (BRMs) to the progression and immunophenotypic landscape of kidney renal clear cell carcinoma (KIRC) remains poorly defined.
Methods: Integrating transcriptomic and clinical data, we established a BRM-based risk signature to refine KIRC prognosis. The model's robustness was validated using the E-MTAB-1980 cohort and a comprehensive nomogram. We employed advanced computational frameworks-including tumor mutation burden (TMB), tumor microenvironment (TME) deconvolution, and drug sensitivity profiling-to dissect biological heterogeneity between risk subgroups.
Results: A nine-BRM signature (comprising L1CAM, MPP7, CLIC5, TUBB2B, PLG, CA8, ITGAX, PADI3, and PRR15L) was identified as an independent prognostic factor. Kaplan-Meier analysis demonstrated significantly inferior survival in the high-risk group (HRG) compared to the low-risk group (LRG) (P < 0.001). The BRM-integrated nomogram exhibited superior predictive accuracy (AUC = 0.747) and strong calibration. Functional enrichment revealed that while the LRG was associated with physiological renal tubular secretion, the HRG was predominantly characterized by immunoglobulin production and B cell-mediated immune dysregulation. Furthermore, the HRG exhibited a significantly higher TMB and distinct sensitivity to Dactolisib and Podophyllotoxin, whereas the LRG favored Docetaxel. RT-qPCR successfully validated the differential expression of core BRMs in clinical samples.
Conclusions: This nine-BRM prognostic model serves as a potential prognostic stratification tool that may complement existing clinical parameters in evaluating the outcomes of KIRC patients.
Keywords: Bone morphogenetic protein; Immunotherapy; Kidney renal clear cell carcinoma; Messenger RNA; Risk model.
© 2026. The Author(s).